{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Yield10 Bioscience, Inc.
Is Yield10 Bioscience, Inc. overvalued or undervalued?
Yield10 Bioscience, Inc. is considered overvalued with a negative P/E ratio and EV to EBITDA, reflecting poor financial performance, and its current price of $0.01 is significantly lower than its 52-week high of $2.33, especially when compared to more attractive peers like CVR Partners LP and Oil-Dri Corp. of America.
Is Yield10 Bioscience, Inc. technically bullish or bearish?
As of February 11, 2025, the market trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, while weekly MACD and KST indicate mild bullishness, resulting in overall indecision.
Who are in the management team of Yield10 Bioscience, Inc.?
As of March 2022, the management team of Yield10 Bioscience, Inc. includes Chairman Robert Van Nostrand, CEO Dr. Oliver Peoples, and Directors Dr. Sherri Brown, Dr. Richard Hamilton, Mr. Joseph Shaulson, and Dr. Anthony Sinskey. They are responsible for the company's strategic direction.
How big is Yield10 Bioscience, Inc.?
As of Jun 13, Yield10 Bioscience, Inc. has a market capitalization of 0.01, classifying it as a Micro Cap company, with net sales of 0.75 million and a net profit of -12.71 million over the last four quarters. As of Dec 23, the company reported shareholder's funds of -2.48 million and total assets of 3.91 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
